ArticleCancer cell international2025

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial.

Peng Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.